Cargando…
Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC
BACKGROUND: Non-small cell lung cancer (NSCLC) patients with primary tumors and liver metastases have substantially reduced survival. Since mesenchymal-epithelial transition factor (MET) plays a significant role in the molecular mechanisms of advanced NSCLC, small molecule MET inhibitor capmatinib (...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717478/ https://www.ncbi.nlm.nih.gov/pubmed/36457016 http://dx.doi.org/10.1186/s12943-022-01681-y |
_version_ | 1784842910161698816 |
---|---|
author | Sun, Yige Yang, Jie Li, Yingbo Luo, Jing Sun, Jiemei Li, Daoshuang Wang, Yuchen Wang, Kai Yang, Lili Wu, Lina Sun, Xilin |
author_facet | Sun, Yige Yang, Jie Li, Yingbo Luo, Jing Sun, Jiemei Li, Daoshuang Wang, Yuchen Wang, Kai Yang, Lili Wu, Lina Sun, Xilin |
author_sort | Sun, Yige |
collection | PubMed |
description | BACKGROUND: Non-small cell lung cancer (NSCLC) patients with primary tumors and liver metastases have substantially reduced survival. Since mesenchymal-epithelial transition factor (MET) plays a significant role in the molecular mechanisms of advanced NSCLC, small molecule MET inhibitor capmatinib (INC280) hold promise for clinically NSCLC treatment. However, the major obstacles of MET-targeted therapy are poor drug solubility and off-tumor effects, even oral high-dosing regimens cannot significantly increase the therapeutic drug concentration in primary and metastatic NSCLC. METHODS: We developed a multirooted delivery system INC280-PFCE nanoparticles (NPs) by loading INC280 into perfluoro-15-crown-5-ether for improving MET-targeted therapy. Biodistribution and anti-MET/antimetastatic effects of NPs were validated in orthotopic NSCLC and NSCLC liver metastasis models in a single low-dose. The efficacy of INC280-PFCE NPs was also explored in human NSCLC specimens. RESULTS: INC280-PFCE NPs exhibited excellent antitumor ability in vitro. In orthotopic NSCLC models, sustained release and prolonged retention behaviors of INC280-PFCE NPs within tumors could be visualized in real-time by (19)F magnetic resonance imaging ((19)F-MRI), and single pulmonary administration of NPs showed more significant tumor growth inhibition than oral administration of free INC280 at a tenfold higher dose. Furthermore, a single low-dose INC280-PFCE NPs administered intravenously suppressed widespread dissemination of liver metastasis without systemic toxicity. Finally, we verified the clinical translation potential of INC280-PFCE NPs in human NSCLC specimens. CONCLUSIONS: These results demonstrated high anti-MET/antimetastatic efficacies, real-time MRI visualization and high biocompatibility of NPs after a single low-dose. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12943-022-01681-y. |
format | Online Article Text |
id | pubmed-9717478 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-97174782022-12-03 Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC Sun, Yige Yang, Jie Li, Yingbo Luo, Jing Sun, Jiemei Li, Daoshuang Wang, Yuchen Wang, Kai Yang, Lili Wu, Lina Sun, Xilin Mol Cancer Research BACKGROUND: Non-small cell lung cancer (NSCLC) patients with primary tumors and liver metastases have substantially reduced survival. Since mesenchymal-epithelial transition factor (MET) plays a significant role in the molecular mechanisms of advanced NSCLC, small molecule MET inhibitor capmatinib (INC280) hold promise for clinically NSCLC treatment. However, the major obstacles of MET-targeted therapy are poor drug solubility and off-tumor effects, even oral high-dosing regimens cannot significantly increase the therapeutic drug concentration in primary and metastatic NSCLC. METHODS: We developed a multirooted delivery system INC280-PFCE nanoparticles (NPs) by loading INC280 into perfluoro-15-crown-5-ether for improving MET-targeted therapy. Biodistribution and anti-MET/antimetastatic effects of NPs were validated in orthotopic NSCLC and NSCLC liver metastasis models in a single low-dose. The efficacy of INC280-PFCE NPs was also explored in human NSCLC specimens. RESULTS: INC280-PFCE NPs exhibited excellent antitumor ability in vitro. In orthotopic NSCLC models, sustained release and prolonged retention behaviors of INC280-PFCE NPs within tumors could be visualized in real-time by (19)F magnetic resonance imaging ((19)F-MRI), and single pulmonary administration of NPs showed more significant tumor growth inhibition than oral administration of free INC280 at a tenfold higher dose. Furthermore, a single low-dose INC280-PFCE NPs administered intravenously suppressed widespread dissemination of liver metastasis without systemic toxicity. Finally, we verified the clinical translation potential of INC280-PFCE NPs in human NSCLC specimens. CONCLUSIONS: These results demonstrated high anti-MET/antimetastatic efficacies, real-time MRI visualization and high biocompatibility of NPs after a single low-dose. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12943-022-01681-y. BioMed Central 2022-12-01 /pmc/articles/PMC9717478/ /pubmed/36457016 http://dx.doi.org/10.1186/s12943-022-01681-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Sun, Yige Yang, Jie Li, Yingbo Luo, Jing Sun, Jiemei Li, Daoshuang Wang, Yuchen Wang, Kai Yang, Lili Wu, Lina Sun, Xilin Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC |
title | Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC |
title_full | Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC |
title_fullStr | Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC |
title_full_unstemmed | Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC |
title_short | Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC |
title_sort | single low-dose inc280-loaded theranostic nanoparticles achieve multirooted delivery for met-targeted primary and liver metastatic nsclc |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717478/ https://www.ncbi.nlm.nih.gov/pubmed/36457016 http://dx.doi.org/10.1186/s12943-022-01681-y |
work_keys_str_mv | AT sunyige singlelowdoseinc280loadedtheranosticnanoparticlesachievemultirooteddeliveryformettargetedprimaryandlivermetastaticnsclc AT yangjie singlelowdoseinc280loadedtheranosticnanoparticlesachievemultirooteddeliveryformettargetedprimaryandlivermetastaticnsclc AT liyingbo singlelowdoseinc280loadedtheranosticnanoparticlesachievemultirooteddeliveryformettargetedprimaryandlivermetastaticnsclc AT luojing singlelowdoseinc280loadedtheranosticnanoparticlesachievemultirooteddeliveryformettargetedprimaryandlivermetastaticnsclc AT sunjiemei singlelowdoseinc280loadedtheranosticnanoparticlesachievemultirooteddeliveryformettargetedprimaryandlivermetastaticnsclc AT lidaoshuang singlelowdoseinc280loadedtheranosticnanoparticlesachievemultirooteddeliveryformettargetedprimaryandlivermetastaticnsclc AT wangyuchen singlelowdoseinc280loadedtheranosticnanoparticlesachievemultirooteddeliveryformettargetedprimaryandlivermetastaticnsclc AT wangkai singlelowdoseinc280loadedtheranosticnanoparticlesachievemultirooteddeliveryformettargetedprimaryandlivermetastaticnsclc AT yanglili singlelowdoseinc280loadedtheranosticnanoparticlesachievemultirooteddeliveryformettargetedprimaryandlivermetastaticnsclc AT wulina singlelowdoseinc280loadedtheranosticnanoparticlesachievemultirooteddeliveryformettargetedprimaryandlivermetastaticnsclc AT sunxilin singlelowdoseinc280loadedtheranosticnanoparticlesachievemultirooteddeliveryformettargetedprimaryandlivermetastaticnsclc |